ContextVision (CONTX) Q3 2025 earnings summary

Executive summary

• Revenue declined 21.2% year-over-year in Q3 2025 due to market turbulence and price pressure in the healthcare sector.

• Strategic progress continued in both Image Quality and Data Quality, with key regulatory approvals enabling patient recruitment for a new clinical study.

• Product portfolio adjusted to align with evolving market dynamics; first clinically focused product launch planned for Q4 at RSNA in Chicago.

• Share buyback program initiated, reflecting confidence in long-term value creation.

Financial highlights

• Q3 2025 revenue was SEK 23.7 million, down 21.2% year-over-year; nine months revenue totaled SEK 78.6 million, down 18.6%.

• Adjusted EBITDA for Q3 was SEK 4 million (16.7% margin); Q3 EBITDA was SEK 1.4 million (5.7% margin).

• Operating cash flow for Q3 was -SEK 2 million; cash position at quarter-end was SEK 67.5 million.

• Equity ratio at period end was 77.6%.

• Q3 earnings per share was 0.00 SEK; adjusted EPS was 0.03 SEK.

Outlook and guidance

• Market conditions expected to remain challenging in the short term due to geopolitical and structural headwinds.

• Confident in long-term strategy and value creation, with continued investment in both business segments.

• New clinically focused product line to launch at RSNA in Chicago in Q4.